Compare MATH & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MATH | COCH |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Blank Checks |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5M | 52.5M |
| IPO Year | 2016 | 2021 |
| Metric | MATH | COCH |
|---|---|---|
| Price | $1.09 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 206.7K | 56.6K |
| Earning Date | 08-06-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $241,000.00 |
| Revenue This Year | N/A | $3.73 |
| Revenue Next Year | N/A | $24.00 |
| P/E Ratio | $3.10 | ★ N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $0.73 | $0.36 |
| 52 Week High | $4.08 | $1.02 |
| Indicator | MATH | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 63.42 | 41.44 |
| Support Level | $1.05 | $0.63 |
| Resistance Level | $1.17 | $0.74 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 92.67 | 16.64 |
Metalpha Technology Holding Ltd mainly operates in the trading of proprietary digital assets and derivative contracts in Hong Kong. The Company's primary business operations center on digital asset services, offered through its subsidiaries. The Company generates income mainly from executing cryptocurrency-related transactions, including providing derivative solutions to over-the-counter (OTC) clients, issuing derivative products to OTC clients, and engaging in proprietary trading activities. The Company provides crypto derivative solutions and liquidity to its clients, facilitated through its principal trading activities, enabling seamless trading of crypto derivative solutions. The Company generates revenue from Hong Kong.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.